| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bio Green Med Solution, Inc.$0.67
-0.01 (-1.99%)
Market Cap
5.35 M
EPS
-4.40
P/E Ratio
-
Value Trade
17.10 K
SEC Financials
Q1 2026Dilution Risk
Revenue
743.00 K
Operating CF
-278.00 K
Total Assets
7.56 M
Total Liabilities
804.00 K
Equity
6.76 M
D/E Ratio
12,345
-9.35 %
Week
-21.14 %
1 Month
-6.73 %
3 Month
-23.62 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.34 M
Monthly Burn
93.00 K
Runway
34.8 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
56.54 K
52 Week Range
0.73 - 29.05
% held by Insiders
42 %
% held by Institutions
2.15 %
Enterprise Value
2.01 M
Total Shares
5.51 M
Short %
0.98 %
Float Shares
3.22 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BGMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BGMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BGMS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BGMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BGMSE xhibit 99.1 Bio Green Med Solution, INC. Announces Business Combination Agreement to acquire Future NRG Sdn. Bhd. Creation of a next-generation environmental platform: The proposed transaction brings together essential
Bio Green Med Solution, Inc. (BGMS) has entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. This deal aims to establish a scalable platform integrating essential safety and environmental services focusing on compliance-driven industries. The combination is anticipated to enhance the service offerings to healthcare waste generators and improve revenue through bundled compliance solutions. Future NRG specializes in sustainable waste management, providing advanced waste-to-energy solutions. The transaction is set to close in the fourth quarter of 2026, pending shareholder approvals.
Read more →BGMSBIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution, Inc. (BGMS) reported its first quarter financial results for 2026, highlighting a strategic shift towards fire safety operations. The company generated $0.8 million in product revenue and reduced general and administrative expenses significantly. Despite a modest net loss of $0.2 million, BGMS maintains a strong cash position to support future growth.
Read more →BGMSBio Green Med Solution, Inc. BIO GREEN MED SOLUTION Reports FIRST quarter financial results and provides business update
Bio Green Med Solution, Inc. announced its first quarter financial results for 2026, showing progress in its strategic transformation. The company reported $0.8 million in revenue from fire safety product sales following the acquisition of Fitters Sdn. Bhd. However, it faced a modest net loss of $0.2 million and dealt with the suspension of trading for its preferred stocks. Despite these challenges, management expressed optimism about future operations and plans to scale in the fire safety sector.
Read more →BGMSBIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution, Inc. (BGMS) reported its fourth quarter and full year 2025 financial results, highlighting a productive year marked by key acquisitions and strategic sales. The company successfully sold its Plogosertib drug and acquired Fitters Sdn. Bhd., shifting its focus to fire safety protection. Despite a net loss of $3.0 million, BGMS declared a quarterly dividend, reflecting ongoing financial management efforts.
Read more →BGMSBio Green Med Solution, Inc. BIO GREEN MED SOLUTION Reports FOURTH quarter AND FULL YEAR 2025 financial results and provides business update
Bio Green Med Solution, Inc. (BGMS) reported its fourth quarter and full year 2025 financial results, highlighting a productive year marked by strategic acquisitions and financial restructuring. The company shifted its focus from biopharmaceuticals to fire safety solutions, including the acquisition of Fitters Sdn. Bhd., which is expected to strengthen its market position. Despite a decline in cash reserves and a reported operating loss, BGMS declared a quarterly cash dividend, indicating its commitment to shareholder value. The transition to a different operational focus underscores the company's strategic pivot in a challenging market environment.
Read more →BGMSBIO GREEN MED SOLUTION Reports THIRD quarter financial results and provides business update
Bio Green Med Solution, Inc. (BGMS) reported its third-quarter financial results, highlighting a strategic shift from biopharmaceutical activities to fire safety solutions. The company recently completed its acquisition of Fitters Sdn. Bhd. and is focusing on expanding its capabilities in fire safety. Despite an increase in cash reserves, the company reported a loss of $1.0 million for the quarter. Additionally, the liquidation of its UK subsidiary has resulted in the loss of R&D tax credits.
Read more →BGMSBio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. Kuala Lumpur, Malaysia
Bio Green Med Solution, Inc. has successfully closed the acquisition of Fitters Sdn. Bhd., a Malaysian-based company specializing in fire safety equipment. This strategic acquisition allows Bio Green Med to diversify its operations beyond pharmaceuticals into the fire protection sector. The deal was validated by stockholder approval and has resulted in Fitters being integrated as a wholly-owned subsidiary. CEO Datuk Dr. Doris Wong noted the potential for exploring new opportunities and creating long-term value for shareholders through this integration.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND quarter financial results and provides business update
Cyclacel Pharmaceuticals, Inc. reported its second quarter financial results for 2025, revealing a cash increase to $4.3 million. Operating expenses decreased significantly from the previous year, leading to an improved net loss of $1.3 million compared to $3.3 million in Q2 2024. However, the liquidation of its UK subsidiary has resulted in the loss of eligibility for research and development tax credits, posing potential challenges for future financing and operational stability.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals COMMENTS ON RECENT STOCK PRICE VOLATILITY Kuala Lumpur, Malaysia
Cyclacel Pharmaceuticals, Inc. addressed recent stock price volatility, indicating that it is unaware of any material changes in its operating conditions. The company reaffirmed that no adverse developments have been disclosed beyond their public announcements, including an amendment to their Exchange Agreement with FITTERS. Cyclacel is actively developing innovative cancer therapies, though they note potential risks associated with stockholder approvals and transaction closure conditions.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT Kuala Lumpur, Malaysia
Cyclacel Pharmaceuticals has announced an amendment to its Exchange Agreement with FITTERS Diversified Berhad, allowing for Fitters Sdn. Bhd. to become a wholly-owned subsidiary. In exchange for shares, Cyclacel will issue common stock equal to 19.99% of its outstanding shares and provide $1 million in cash. The agreement was unanimously approved by the boards of both companies, but is contingent on stockholder approval and regulatory clearances. The expected closing date has been extended to September 30, 2025.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. has announced a 1-for-15 reverse stock split effective July 7, 2025. This decision, approved by both the board of directors and shareholders, aims to enhance the stock's marketability without altering shareholder percentage interest. Post-split, the number of issued shares will decrease from approximately 23.76 million to about 1.58 million. Cyclacel is developing innovative cancer treatments, including plogosertib, while facing inherent risks in clinical developments and market dynamics.
Read more →BGMSCYCLACEL PHARMACEUTICALS ANNOUNCES $3
Cyclacel Pharmaceuticals, Inc. has announced a private placement offering of convertible preferred stock, yielding gross proceeds of $3 million. The funding will be utilized for working capital and general corporate purposes, potentially extending the company's cash runway into the third quarter of 2025. Additionally, investors will receive purchase warrants for shares of common stock at specified exercise prices. This financing aligns with Cyclacel's ongoing development of innovative cancer medicines.
Read more →BGMSCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequiremenT
Cyclacel Pharmaceuticals, Inc. has announced that it has regained compliance with the Nasdaq Minimum Bid Price Requirement as of June 3, 2025. The company received a Compliance Notice indicating that its stock price has met the required $1.00 minimum for a consecutive 15-day period from May 12 to June 2, 2025. This follows a previous notification in December 2024 regarding non-compliance. The achievement reflects positively on Cyclacel's standing on the Nasdaq Stock Market.
Read more →BGMSCyclacel Pharmaceuticals Reports FIRST quarter financial results and provides business update
Cyclacel Pharmaceuticals has announced its first-quarter financial results, highlighting a focus on developing plogosertib following the liquidation of its subsidiary, Cyclacel Limited. The company reported a gain of approximately $5.0 million from the deconsolidation of Cyclacel Limited, although it also anticipates a significant decrease in research and development expenses. The ongoing analysis of strategic alternatives reflects a challenging funding environment. As of March 31, 2025, the company's cash balance stood at $3.5 million, which they estimate will support planned programs into the second quarter.
Read more →BGMSCyclacel Pharmaceuticals, INC. Announces EXECUTION OF Share Exchange Agreement to Make Fitters Sdn. Bhd. its Wholly-owned Subsidiary to Accelerate Growth and STOCKholder Value
Cyclacel Pharmaceuticals, Inc. announced the execution of a Share Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysian subsidiary of FITTERS Diversified Berhad. This strategic move is designed to accelerate growth and enhance shareholder value. Upon finalizing the transaction, Cyclacel will issue shares equivalent to 19.99% of its common stock to FITTERS, and its stockholders are expected to maintain an 80.01% ownership stake. The completion of the transaction is subject to approval from both companies’ stockholders.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FOURTH quarter financial results and provides business update
Cyclacel Pharmaceuticals, Inc. reported its fourth quarter financial results and outlined a strategic focus on the development of plogosertib, a treatment for advanced cancers. The company initiated the liquidation of Cyclacel Limited, resulting in a significant reduction of operating costs and research and development expenses. The deconsolidation is expected to boost stockholders' equity, despite reporting a net loss of $11.2 million for the year. The appointment of new board members aims to strengthen governance as the company navigates through its challenges.
Read more →BGMSCYCLACEL PHARMACEUTICALS ANNOUNCES $1
Cyclacel Pharmaceuticals announced a $1 million private placement of convertible preferred stock to accredited investors. This financing aims to support working capital requirements and is anticipated to extend the company's cash runway into the third quarter of 2025. Each convertible share is designated to convert into common stock pending stockholder approval, and the offering was executed independently by the company without an underwriter.
Read more →BGMSCYCLACEL PHARMACEUTICALS ANNOUNCES CLOSING OF A
Cyclacel Pharmaceuticals announced a significant change in control and leadership following the acquisition of 70% of its shares by Datuk Dr. Doris Wong Sing Ee. This transaction involved a total consideration of $6.3 million and resulted in her election as CEO, succeeding former interim CEO David Lazar. Alongside her, Kiu Cu Seng was appointed as Executive Director and CFO. Several board members resigned on the same date, paving the way for new governance aimed at driving the company’s growth and value creation.
Read more →BGMSInvestors Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar Jan 03 2025 David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim
Cyclacel Pharmaceuticals announced a securities purchase agreement with investor David Lazar, who will invest $3.1 million in preferred stock, becoming the interim CEO. The investment aims to aid in settling outstanding liabilities and other corporate purposes. However, the company faces risks, including the need for stockholder approvals for the transaction and potential delisting from Nasdaq if compliance is not regained by February 2025. The Board of Directors will also see changes, impacting the company's strategic direction.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES CLOSING OF EXERCISE OF WARRANTS FOR $2.1
Cyclacel Pharmaceuticals, Inc. has announced the successful closing of its warrant exercise transaction, yielding gross proceeds of $2.1 million. The company issued new Series C and Series D warrants, increasing future potential capital. The proceeds will be used for working capital and corporate purposes. Cyclacel's ongoing focus is on developing innovative cancer medicines and advancing its drug pipeline in the oncology sector.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD quarter financial results and provides business update
Cyclacel Pharmaceuticals reported its third-quarter financial results, revealing important data on fadraciclib’s efficacy in treating advanced solid tumors. The company is under pressure to secure additional funding to meet Nasdaq's minimum stockholders' equity requirement by December 24, 2024. Despite reporting a reduction in operating expenses, Cyclacel faces significant challenges regarding its ability to continue operations and potential delisting from the Nasdaq. Its available cash is projected to fund current programs only until the fourth quarter of 2024.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES T hat
Cyclacel Pharmaceuticals, Inc. announced it has received a notice from Nasdaq granting an extension until December 24, 2024, to regain compliance with the stockholders' equity requirement. This follows a determination that the company did not meet the minimum equity requirement, reporting less than $2.5 million as of June 30, 2024. The current notice does not affect the company's listing status on Nasdaq immediately, but there are uncertainties regarding future compliance.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND quarter financial results and provides business update - Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well - - 065-101 PoC Interim Data
Cyclacel Pharmaceuticals reported its second quarter financial results, showcasing strong enrollment for the Phase 2 proof of concept study of fadraciclib, with initial data expected in Q4 2024. The company noted a significant reduction in net losses compared to the previous year, aided by an increase in cash from financing activities. Management expressed optimism about continuing clinical progress, albeit with noteworthy operational challenges and a still significant net loss.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports first quarter financial results and provides business update - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Med
Cyclacel Pharmaceuticals reported its first quarter financial results, highlighting patient enrollment in the Phase 2 proof of concept study of its oral CDK2/9 inhibitor fadraciclib. The company strengthened its financial position with an $8 million private placement. Additionally, key data on the safety and efficacy of fadraciclib will be presented at the upcoming ASCO Annual Meeting. However, the company also noted an operating loss that has increased compared to the previous year, signaling ongoing financial challenges.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES $8.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET
Cyclacel Pharmaceuticals, Inc. has announced a private placement raising $8.0 million through the sale of nearly 4.97 million shares of common stock and associated warrants. The offering is priced at $1.61 per share and will be conducted under Nasdaq rules, with the aim to close around May 2, 2024. Proceeds from the offering will be allocated to working capital and other corporate purposes, supporting the company’s focus on developing innovative cancer treatments. However, the securities will not be registered under the Securities Act, posing potential limitations for investors.
Read more →BGMSCyclacel Pharmaceuticals Reports fourth quarter and full year 2023 financial results and provides business update - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 - - Expect to Report Final Data f
Cyclacel Pharmaceuticals has reported its fourth quarter and full year 2023 financial results, indicating improvements in operational cash usage and preparing for potential breakthroughs in cancer treatment. The company is set to initiate a Phase 2 proof-of-concept study for oral fadraciclib in the first half of 2024, with two key data readouts expected this year. Additionally, advancements in precision medicine for ARID1A- and SMARCA-mutated cancers are being pursued with its other compound, plogosertib. Financially, while cash reserves have decreased compared to the previous year, management anticipates their current funding will carry them into the second quarter of 2024.
Read more →BGMSCyclacel Pharmaceuticals, Inc. (CYCC) BIOTECH SHOWCASE JANUARY 2024 Translating cancer biology into medicines Disclaimer This presentation contains certain forward-looking statements that involve risks and uncertainties
Cyclacel Pharmaceuticals presented at the January 2024 Biotech Showcase, highlighting advancements in their cancer treatments, particularly with oral medications CYC065 and CYC140. The company aims to advance to Phase 2 trials for CYC065, targeting solid tumors, while CYC140 is undergoing further dose escalation in its trials. Their innovative approaches focus on exploiting epigenetic mechanisms to enhance treatment efficacy in various cancers, underscoring their commitment to addressing unmet medical needs.
Read more →BGMSCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
Cyclacel Pharmaceuticals has announced a registered direct and private placement offering of common stock priced at $3.315 per share, aiming to raise approximately $1.3 million. The offering includes the sale of 388,200 shares, with the closing expected on December 26, 2023, subject to customary conditions. The funds are intended for working capital and general corporate purposes, increasing the company's liquidity as it develops its pipeline of cancer therapies.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD quarter financial results and provides business update - Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadracicl
Cyclacel Pharmaceuticals reported its third-quarter financial results and provided updates on its clinical programs. The company anticipates presenting updated Phase 1/2 clinical and biomarker data for its drug candidates, fadraciclib and plogosertib, highlighting their anticancer activities and tolerability. Despite promising clinical observations, Cyclacel faces financial challenges, with a decrease in cash reserves and an increase in net losses compared to the previous year. The company aims to sustain its operations through the end of 2023 and hopes to extend its runway into the second quarter of 2024.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND quarter financial results and provides business update - Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2
Cyclacel Pharmaceuticals reported its second quarter financial results and provided an update on its ongoing clinical trials. The company is moving forward with its Phase 1/2 clinical trials for fadraciclib, a next-generation CDK inhibitor, and plogosertib, a novel PLK1 inhibitor, with promising initial data suggesting their potential efficacy. However, the company also reported a net loss of $5.4 million for the quarter and a significant drop in cash reserves. Key milestones are expected in the coming months as the company evaluates both drug candidates further.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports first quarter financial results and provides business update - Key Catalysts ahead with multiple Value Generating Readouts - - Expects to Report Phase 1/2 D
Cyclacel Pharmaceuticals reported its first-quarter financial results, highlighting significant advances in clinical programs for its oral drugs fadraciclib and plogosertib. The company expects to release important data from ongoing Phase 1/2 studies that could validate these drugs' unique efficacy in treating advanced solid tumors and lymphoma. Additionally, Cyclacel secured $4.7 million from an R&D tax credit to bolster its operations, although the company reported an increased net loss compared to the prior year. The management remains optimistic about upcoming milestones and data releases, which are crucial for the company's future.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports fourth quarter and full year 2022 financial results and provides business update - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 an
Cyclacel Pharmaceuticals, Inc. has reported its fourth quarter and full year 2022 financial results, announcing a strong outlook for 2023. The company plans to initiate Phase 2 proof-of-concept trials for oral fadraciclib in multiple cancer cohorts and anticipates key data readouts later this year. Additionally, Cyclacel is advancing oral plogosertib and has reported encouraging results from earlier phases of both drug candidates. Despite facing increased losses and cash burn, management remains optimistic about the potential of its clinical pipeline.
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD quarter 2022 financial results and provides business update - Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Es
Pharmaceuticals Reports THIRD quarter 2022 financial results and provides business update Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - Two Partial Responses in Lympho
Read more →BGMSCyclacel Pharmaceuticals Reports SECOND quarter 2022 financial results and provides business update - Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 20
Pharmaceuticals Reports SECOND quarter 2022 financial results provides business update Oral fadraciclib demonstrated good tolerability with continuous dosing; entering Phase 2 POC stage in 2H 2022 - - Demonstrated evidence of target engagement for CDK2 and CDK9 - Company to
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyc lacel Pharmaceuticals Reports first quarter 2022 financial results and provides business update - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate
Pharmaceuticals Reports first quarter 2022 financial results and provides business update Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS -Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 -
Pharmaceuticals Reports FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 - Call Scheduled for March 28, 2022, at 4:30 p.m. EDT- BERKELEY HEIGHTS, NJ, March 28, 2022 - Cyclacel Phar
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD Quarter 2021 Financial Results AND PROVIDES BUSINESS UPDATE - Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia - - Cash Runway
Pharmaceuticals Reports THIRD Quarter 2021 Financial Results PROVIDES BUSINESS UPDATE - Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia - - Cash Runway to Early 2023 - - Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - Berkeley Heights
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND Quarter 2021 Financial Results AND PROVIDES BUSINESS UPDATE - Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional P
Pharmaceuticals Reports SECOND Quarter 2021 Financial Results PROVIDES BUSINESS UPDATE Patients with Solid Tumors Dosed with Oral Fadraciclib - 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - Scheduled August 11, 2021 at 4:30 p.m. ET - Berkeley Heights, NJ, August
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FIRST Quarter 2021 Financial Results - Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - - Recent Publication Report
Pharmaceuticals Reports FIRST Quarter 2021 Financial Results Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition - Following Recent Financing, Cash Run
Read more →BGMSCyclacel Pharmaceuticals, Inc . CYCLACEL PHARMACEUTICALS PRICES $12.65 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, New Jersey
PHARMACEUTICALS PRICES $12.65 MILLION PUBLIC OFFERING OF COMMON STOCK Heights, New Jersey, March 12, 2021 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer ce
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Conference Call Scheduled February 25, 2021 at 4:30 p.m. EDT - Berkeley Heights, NJ, February 25, 2021 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biop
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES At-the-market $7 MILLION strategic INVESTMENT BY FUNDAMENTAL INVESTOR ACORN BIOVENTURES - Strategic investment from single biotech-focused institutional i
Pharmaceuticals ANNOUNCES At-the-market $7 MILLION strategic INVESTMENT BY FUNDAMENTAL INVESTOR ACORN BIOVENTURES Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignanci
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD Quarter 2020 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports THIRD Quarter 2020 Financial Results Call Scheduled November 11, 2020 at 4:30 p.m. ET - Berkeley Heights, NJ, November 11, 2020 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company dev
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals ANNOUNCES APPOINTMENT OF MARK KIRSCHBAUM, m.d., AS CHIEF MEDICAL OFFICER Berkeley Heights, NJ
Pharmaceuticals ANNOUNCES APPOINTMENT OF MARK KIRSCHBAUM, m.d., AS CHIEF MEDICAL OFFICER Berkeley Heights, NJ, October 23, 2020 Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND Quarter 2020 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports SECOND Quarter 2020 Financial Results Call Scheduled August 12, 2020 at 4:30 p.m. ET - Berkeley Heights, NJ, August 12, 2020 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company develo
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FIRST Quarter 2020 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports FIRST Quarter 2020 Financial Results Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - Following Recent Financing Cash Runway to End of 2022 - Heights, NJ, May 12, 2020 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Announces PRICING OF $20 MILLION PUBLIC OFFERING Berkeley Heights, NJ
Announces PRICING OF $20 MILLION PUBLIC OFFERING NJ, April 21, 2020 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF EDINBURGH TO STUDY ITS CDK INHIBITORS TO REDUCE RUNAWAY INFLAMMATION IN COVID-19 DISEASE -Evaluation of Fadraciclib a
CYCLACEL PHARMACEUTICALS ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF EDINBURGH TO STUDY ITS CDK INHIBITORS TO REDUCE RUNAWAY INFLAMMATION IN COVID-19 DISEASE Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury-
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results - Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor an
Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results - Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL -
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports THIRD Quarter 2019 Financial Results - Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent- - Conference Call Scheduled
Pharmaceuticals Reports THIRD Quarter 2019 Financial Results - Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent- Call Scheduled November 13, 2019 at 4:30 p.m. ET - Berkeley Heights, NJ, Wednesday, November 13, 2019 - Cyclacel Pharmaceuticals,
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports second Quarter 2019 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports second Quarter 2019 Financial Results Call Scheduled August 13, 2019 at 4:30 p.m. ET - Berkeley Heights, NJ, August 13, 2019 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company develo
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FIRST Quarter 2019 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports FIRST Quarter 2019 Financial Results Call Scheduled May 14, 2019 at 4:30 p.m. ET - Berkeley Heights, NJ, May 14, 2019 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing in
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - Conference Call Scheduled
Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 27, 2019 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biophar
Read more →BGMSCyclacel Pharmaceuticals Reports ThIRD Quarter 2018 Financial Results - Conference Call Scheduled
- Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET - Berkeley Heights, NJ, November 12, 2018 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cel
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS AND MD ANDERSON CANCER CENTER ANNOUNCE STRATEGIC ALLIANCE TO STUDY NOVEL CYCLACEL MEDICINES IN HEMATOLOGICAL MALIGNANCIES - Multi-product agreement builds on long-t
CYCLACEL PHARMACEUTICALS AND MD ANDERSON CANCER CENTER ANNOUNCE STRATEGIC ALLIANCE TO STUDY NOVEL CYCLACEL MEDICINES IN HEMATOLOGICAL - Multi-product agreement builds on long-term clinical collaboration in hematological malignancies- Berkeley Heights, NJ and Houston, TX, Octob
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS APPOINTS ROBERT J. SPIEGEL, M.D. TO BOARD OF DIRECTORS -Former CMO of Schering-Plough Joins Cyclacel Board - Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS APPOINTS ROBERT J. SPIEGEL, M.D. TO BOARD OF DIRECTORS -Former CMO of Schering-Plough Joins Berkeley Heights, NJ, September 12, 2018 - Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports SECOND Quarter 2018 Financial Results -- Conference Call Scheduled
Pharmaceuticals Reports SECOND Quarter 2018 Financial Results Call Scheduled August 9, 2018 at 4:30 p.m. EDT - Berkeley Heights, NJ, August 9, 2018 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company develop
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports FIRST Quarter 2018 Financial Results -- Conference Call Scheduled
Pharmaceuticals Reports FIRST Quarter 2018 Financial Results Call Scheduled May 14, 2018 at 4:30 p.m. EDT - Berkeley Heights, NJ, May 14, 2018 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing o
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results -- Conference Call Scheduled
Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results -- Conference Call Scheduled March 28, 2018 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 28, 2018 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopha
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Announces PRESENTATION OF RESULTS FROM PHASE 3 SEAMLESS STUDY AT ASH ANNUAL MEETING Berkeley Heights, NJ
Announces PRESENTATION OF RESULTS FROM PHASE 3 STUDY AT ASH ANNUAL MEETING Berkeley Heights, NJ, December 12, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target va
Read more →BGMSCYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS -- Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Call Scheduled November 9, 2017 at 4:30 p.m. ET - Berkeley Heights, NJ, November 9, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical com
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Conference Call Scheduled August 9, 2017 at 4:30 p.m. EDT - Berkeley Heights, NJ, August 9, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a clinical-stag
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES SELECTION OF RECOMMENDED PHASE 2 DOSE FOR CYC065 AND EVIDENCE OF DURABLE TARGET ENGAGEMENT AND MCL-1 BIOMARKER SUPPRESSION - Part 2 of study will focus on cyclin E amplif
CYCLACEL ANNOUNCES SELECTION OF RECOMMENDED PHASE 2 DOSE FOR CYC065 AND EVIDENCE OF DURABLE TARGET ENGAGEMENT AND MCL-1 BIOMARKER SUPPRESSION - Part 2 of study will focus on cyclin E amplified drug resistant solid tumors - Berkeley Heights, NJ, August 7, 2017 - Cyclacel Ph
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES CLOSING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING AND FULL EXERCISE OF OVER-ALLOTMENT OPTION Berkeley Heights, NJ
CYCLACEL ANNOUNCES CLOSING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING AND FULL EXERCISE OF OVER-ALLOTMENT OPTION Berkeley Heights, NJ, July 21, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES PRICING OF $13.2 MILLION UNDERWRITTEN PUBLIC OFFERING Berkeley Heights, NJ
CYCLACEL ANNOUNCES PRICING OF $13.2 MILLION UNDERWRITTEN PUBLIC OFFERING Berkeley Heights, NJ, July 19, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT - Berkeley Heights, NJ, May 11, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS -- Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS Call Scheduled March 28, 2017 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 28, 2017 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmace
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 SEAMLESS study IN elderly patients with Acute myeloid leukemia - Study did not reach statistically significant improvement in the pr
ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 SEAMLESS study elderly patients with Acute myeloid leukemia - Study did not reach statistically significant improvement in the primary endpoint of overall survival - - Improvement in secondary endpoint of complete remission rat
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS 3 rd QUARTER 2016 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS 3rd QUARTER 2016 FINANCIAL RESULTS Call Scheduled November 14, 2016 at 4:30 p.m. ET BERKELEY HEIGHTS, NJ, Nov. 14, 2016 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company
Read more →BGMSREPORTS 2ND QUARTER 2016 FINANCIAL RESULTS
CYCLACEL PHARMACEUTICALS REPORTS 2ND QUARTER 2016 FINANCIAL RESULTS Call Scheduled August 10, 2016 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J., Aug. 10, 2016 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical compa
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Announces REVERSE STOCK SPLIT Berkeley Heights, NJ
Announces REVERSE STOCK SPLIT NJ, May 27, 2016 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer an
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT - Berkeley Heights, NJ, May 11, 2016 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutic
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Announces Receipt of NASDAQ Extension Berkeley Heights, NJ
Announces Receipt of NASDAQ Extension Berkeley Heights, NJ, April 11, 2016 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control fo
Read more →BGMSCYCLACEL PHARMACEUTICALS REPORTS FOURTH
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS - Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 24, 2016 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company")
Read more →BGMSAnnounces Receipt of NASDAQ Staff Determination;
Announces Receipt of NASDAQ Staff Determination; BERKELEY HEIGHTS, N.J., February 5, 2016 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC; CYCCP) ("Cyclacel" or the "Company") today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Conference Call Scheduled
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Call Scheduled November 12, 2015 at 4:30 p.m. EST BERKELEY HEIGHTS, N.J., Nov. 12, 2015 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical co
Read more →BGMSCyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Conference Call Scheduled
Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Call Scheduled August 11, 2015 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J., Aug. 11, 2015 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical com
Read more →BGMSCYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Approximately 20% of prespecified events remaining in SEAMLESS before study unblinding - - Received FDA clearance for the first-in-human Phase 1 stu
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Approximately 20% of prespecified events remaining in SEAMLESS before study unblinding - - Received FDA clearance for the first-in-human Phase 1 study of CYC065 CDK inhibitor - - Conference Call Schedul
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS - Conference Call Scheduled March 24, 2015 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 24, 2015 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company")
Read more →BGMSANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
CYCLACEL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ, March 3, 2015 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the v
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES ENROLLMENT OF 486 PATIENTS, DSMB RECOMMENDATIONS AND THAT THE SEAMLESS PHASE 3 TRIAL OF SAPACITABINE IN AML WILL CONTINUE TO FINAL ANALYSIS - DSMB determined that the pla
CYCLACEL ANNOUNCES ENROLLMENT OF 486 PATIENTS, DSMB RECOMMENDATIONS AND THAT THE SEAMLESS PHASE 3 TRIAL OF SAPACITABINE IN AML WILL CONTINUE TO FINAL ANALYSIS - DSMB determined that the planned futility boundary but saw no reason for patients to discontinue - Conference Call
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Conference Call Scheduled November 11, 2014 at 4:30 p.m. EST - Berkeley Heights, NJ, November 11, 2014 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a bioph
Read more →BGMSCell Cycle to Treat AML and MDS
Cell Cycle to Treat AML and MDS BioCentury Newsmakers in the Biotech Industry Conference contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, busin
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS APPOINTS SAMUEL L. BARKER, PH.D., TO BOARD OF DIRECTORS Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS APPOINTS SAMUEL L. BARKER, PH.D., TO BOARD OF DIRECTORS Berkeley Heights, NJ, September 11, 2014 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company") announced today the appointment of Samuel L. Barker, Ph.D., t
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Conference Call Scheduled August 12, 2014 at 4:30 p.m. EDT - Berkeley Heights, NJ, August 12, 2014 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharm
Read more →BGMSCyclacel Pharmaceuticals, Inc. P R E S S R E L E A S E CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS -- Conference Call Scheduled
P R E S S R E L E A S E PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Conference Call Scheduled May 13, 2014 at 4:30 p.m. EDT -- Heights, NJ, May 13, 2014 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmace
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ, April 3, 2014 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company) today announced that it intends to offer, subject to market and other condit
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites - Confe
CYCLACEL PHARMACEUTICALS REPORTS FOURTH FULL YEAR 2013 FINANCIAL RESULTS European Expansion of SEAMLESS Phase 3 Study Initiated; Potentially Trebling Participating Sites - Conference Call Scheduled March 25, 2014 at 4:30 p.m. EDT - Berkeley Heights, NJ, March 25, 2014 - Cy
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on
CYCLACEL REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on November 12, 2013 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, November 12, 2013 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical comp
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on
Cyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on August 14, 2013 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, August 14, 2013 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Compa
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS ANNOUNCES CLOSING OF UNDERWRITTEN OFFERING Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS ANNOUNCES CLOSING OF UNDERWRITTEN OFFERING Berkeley Heights, NJ, May 21, 2013 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), today announced that it has closed its previously announced underwritten offering of 6,83
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on
CYCLACEL REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Conference Call Scheduled on May 13, 2013 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, May 13, 2013 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company develo
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES SALE OF FOUR CYCLACEL ROMIDEPSIN-RELATED PATENTS TO CELGENE AND DISMISSAL OF ALL CLAIMS IN THEIR PATENT LITIGATION Berkeley Heights, NJ
CYCLACEL ANNOUNCES SALE OF FOUR CYCLACEL ROMIDEPSIN-RELATED PATENTS TO CELGENE AND DISMISSAL OF ALL CLAIMS IN THEIR PATENT LITIGATION Berkeley Heights, NJ, April 4, 2013 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) ( Cyclacel or the Company ) announced that it
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS Conference Call Scheduled March 27, 2013 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, March 27, 2013 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company )
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ENTERS INTO A $20 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC Proceeds to advance SEAMLESS, the ongoing Phase 3 trial of sapacitabine in elderly patients
CYCLACEL ENTERS INTO A $20 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC Proceeds to advance SEAMLESS, the ongoing Phase 3 trial of sapacitabine in elderly patients with newly diagnosed AML Berkeley Heights, NJ, December 17, 2012 Cyclacel Pharmaceutica
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Enrollment in SEAMLESS Phase 3 study of sapacitabine proceeding as planned; updated survival data from the pilot/lead-in stage of SEA
CYCLACEL REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Enrollment in SEAMLESS Phase 3 study of sapacitabine proceeding as planned; updated survival data from the pilot/lead-in stage of SEAMLESS to be presented at the upcoming annual meeting of the American Society of Hematolo
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE LISTING REQUIREMENT Berkeley Heights, NJ
CYCLACEL REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE LISTING REQUIREMENT Berkeley Heights, NJ, September 13, 2012 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the var
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES REVERSE STOCK SPLIT Stock will begin trading on split-adjusted basis on
CYCLACEL ANNOUNCES REVERSE STOCK SPLIT Stock will begin trading on split-adjusted basis on August 27, 2012 Berkeley Heights, NJ, August 24, 2012 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing oral th
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Conference Call Scheduled August 14, 2012 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, August 14, 2012 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company de
Read more →BGMSCyclacel Pharmaceuticals, Inc **** IMPORTANT ****
Dear Cyclacel Pharmaceuticals, Inc. Shareholder: Enclosed you will find an additional proxy form relating to Cyclacel Pharmaceutical s Annual Meeting of Shareholders to be held on May 23, 2012. At our annual meeting, shareholders will act upon: the election of directors, to a
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Conference Call Scheduled May 14, 2012 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, May 14, 2012 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developin
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS Conference Call Scheduled March 29, 2012 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, March 29, 2012 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company )
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES $3.0 MILLION FINANCING TO FUND ONGOING LITIGATION EXPENSES ON CERTAIN INTELLECTUAL PROPERTY Berkeley Heights, NJ
CYCLACEL ANNOUNCES $3.0 MILLION FINANCING TO FUND ONGOING LITIGATION EXPENSES ON CERTAIN INTELLECTUAL PROPERTY Berkeley Heights, NJ, March 22, 2012 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ), today announced that the Company entered i
Read more →BGMSCyclacel Pharmaceuticals, Inc. PRESS RELEASE CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS SEAMLESS Phase 3 trial design simplified; FDA confirmed that SPA remains valid Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS SEAMLESS Phase 3 trial design simplified; FDA confirmed that SPA remains valid Conference Call Scheduled November 14, 2011 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, November 14, 2011 Cyclacel Pharmaceu
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS RECEIVES DEFICIENCY NOTICE FROM NASDAQ GLOBAL SELECT MARKET Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS RECEIVES DEFICIENCY NOTICE FROM NASDAQ GLOBAL SELECT MARKET Berkeley Heights, NJ, September 22, 2011 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), today announced that it received a Nasdaq Staff Deficiency Letter
Read more →BGMSCyclacel Pharmaceuticals, Inc. PRESS RELEASE CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS Conference Call Scheduled August 11, 2011 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, August 11, 2011 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), announced tod
Read more →BGMSCYCLACEL PHARMACEUTICALS, INC. ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS - Proceeds to advance SEAMLESS pivotal Phase 3 trial of oral sapacitabine - Berkeley Heights, NJ
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS - Proceeds to advance SEAMLESS pivotal Phase 3 trial of oral sapacitabine - Berkeley Heights, NJ, July 1, 2011 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; C
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2011 Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2011 Conference Call Scheduled May 12, 2011 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, May 12, 2011 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceuti
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2010 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2010 FINANCIAL RESULTS Conference Call Scheduled March 23, 2011 at 4:30 p.m. Eastern Time Berkeley Heights, NJ, March 23, 2011 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company),
Read more →BGMSCYCLACEL BEGINS PIVOTAL PHASE 3 "SEAMLESS" TRIAL OF SAPACITABINE AS FRONT-LINE TREATMENT FOR AML UNDER A SPECIAL PROTOCOL ASSESSMENT - Cyclacel to host conference call at 4:30 pm ET on Tuesday
CYCLACEL BEGINS PIVOTAL PHASE 3 "SEAMLESS" TRIAL OF SAPACITABINE AS FRONT-LINE TREATMENT FOR AML UNDER A SPECIAL PROTOCOL ASSESSMENT - Cyclacel to host conference call at 4:30 pm ET on Tuesday, January 18, 2011 to discuss study design Berkeley Heights, NJ, January 11, 2011
Read more →BGMSCYCLACEL ANNOUNCES TOPLINE RESULTS FROM THE APPRAISE PHASE 2B STUDY OF SELICICLIB IN HEAVILY-PRETREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER Berkeley Heights, NJ
CYCLACEL ANNOUNCES TOPLINE RESULTS FROM THE APPRAISE PHASE 2B STUDY OF SELICICLIB IN HEAVILY-PRETREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER Berkeley Heights, NJ, December 21, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ), a bi
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2010
CYCLACEL PHARMACEUTICALS REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS BERKELEY HEIGHTS, NJ November 11, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control
Read more →BGMSCYCLACEL
CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT BERKELEY HEIGHTS, NJ October 7, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treat
Read more →BGMSCyclacel Pharmaceuticals, Inc.
CYCLACEL ANNOUNCES ADJOURNMENT OF SPECIAL PREFERRED STOCKHOLDERS MEETING BERKELEY HEIGHTS, NJ October 6, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control
Read more →BGMSCYCLACEL ANNOUNCES PRIVATE PLACEMENT FINANCING FOR UP TO $22.1 MILLION - Proceeds to advance SEAMLESS pivotal Phase 3 trial of oral sapacitabine
CYCLACEL ANNOUNCES PRIVATE PLACEMENT FINANCING FOR UP TO $22.1 MILLION - Proceeds to advance SEAMLESS pivotal Phase 3 trial of oral sapacitabine - BERKELEY HEIGHTS, NJ October 5, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company dev
Read more →BGMSCYCLACEL PHARMACEUTICALS REACHES AGREEMENT WITH FDA ON A SPECIAL PROTOCOL ASSESSMENT FOR PIVOTAL PHASE 3
CYCLACEL PHARMACEUTICALS REACHES AGREEMENT WITH FDA PROTOCOL ASSESSMENT FOR PIVOTAL PHASE 3 TRIAL OF SAPACITABINE IN AML BERKELEY HEIGHTS, NJ - September 13, 2010 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral thera
Read more →BGMSCYCLACEL PHARMACEUTICALS 6%
CYCLACEL PHARMACEUTICALS 6% CONVERTIBLE EXCHANGEABLE PREFERRED STOCKHOLDERS REQUEST SPECIAL MEETING TO ELECT DIRECTORS BERKELEY HEIGHTS, NJ August 13, 2010 Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC ) (Nasdaq: CYCCP), a biopharmaceutical company developing oral therapies tha
Read more →BGMSCyclacel Pharmaceuticals, Inc. PRESS RELEASE CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2010
CYCLACEL PHARMACEUTICALS REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS BERKELEY HEIGHTS, NJ August 5, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control f
Read more →BGMSCyclacel Pharmaceuticals, Inc. P R E S S R E L E A S E CYCLACEL PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2010 Conference Call Scheduled
P R E S S R E L E A S E CYCLACEL PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2010 Conference Call Scheduled May 13, 2010 at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ May 13, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutic
Read more →BGMSCYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2009 FINANCIAL RESULTS Conference Call Scheduled
CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2009 FINANCIAL RESULTS Conference Call Scheduled March 23, 2010 at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ March 23, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) a
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL REGAINS NASDAQ COMPLIANCE Berkeley Heights, NJ
Cyclacel Pharmaceuticals, Inc. CYCLACEL REGAINS NASDAQ COMPLIANCE Berkeley Heights, NJ, January 27, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) today announced that NASDAQ notified the Company that it has regained compliance wit
Read more →BGMSCyclacel Pharmaceuticals, Inc. CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING Berkeley Heights, NJ
Cyclacel Pharmaceuticals, Inc. CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING Berkeley Heights, NJ, January 25, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) announced today that it completed its previously anno
Read more →BGMSCYCLACEL TO RAISE UP TO $7.9 MILLION IN REGISTERED DIRECT OFFERING Berkeley Heights, NJ
CYCLACEL TO RAISE UP TO $7.9 MILLION IN REGISTERED DIRECT OFFERING Berkeley Heights, NJ, January 21, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) announced today that it has entered into definitive agreements to raise $5.9 million
Read more →BGMSCyclacel Pharmaceuticals, Inc. P R E S S R E L E A S E CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING Berkeley Heights, NJ
Cyclacel Pharmaceuticals, Inc. P R E S S R E L E A S E CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING Berkeley Heights, NJ, January 13, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) announced today that it comp
Read more →BGMSCyclacel Pharmaceuticals, Inc. PRESS RELEASE CYCLACEL TO RAISE UP TO $9.5 MILLION IN REGISTERED DIRECT OFFERING Berkeley Heights, NJ
CYCLACEL TO RAISE UP TO $9.5 MILLION IN REGISTERED DIRECT OFFERING Berkeley Heights, NJ, January 11, 2010 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ) announced today that it has entered into definitive agreements to raise $7.2 million
Read more →Competitive Position
How BGMS ranks across every disease it competes inCompetitive Position is a premium feature
See how BGMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial